31/07/2018

ESTEVE’S RDI, AGAIN RATED ’EXCELLENT’ BY THE PROFARMA PLAN

The Profarma Plan (Plan for the Promotion of Scientific Research, Development and Technological Innovation in the Pharmaceutical Industry), a joint program of the Ministry of Industry, Energy and Tourism and of the Ministry of Health, Social Services and Equality, has again rated ESTEVE’s RDI as 'excellent'

This rating acknowledges the company’s commitment to innovation, with an important part of its workforce devoted to top-level research. Over the last year, ESTEVE has invested more than 81 million Euros in R&D.

ESTEVE appears in Group A of the Profarma Plan (2017-2020), which includes companies that conduct significant research activities and have their own center of production or basic or preclinical R&D.

The main purpose of the Profarma Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector, strengthening the activities that provide the highest added value, and fostering research, development and innovation.

Last news

  • ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE

    Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europe

    read more
  • POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN

    The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugs

    read more
  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.